메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Nexus Aesthetic Clinic Founder Dr. Samantha Tay Advocates for Enhanced Patient Safety in Aesthetic Medicine

[ 메디채널 김갑성 기자 ] Founder of Nexus Aesthetic Clinic addresses public concerns about injectables and highlights the importance of professional oversight. SINGAPORE, Sept. 12, 2025 -- Amid a growing public conversation about the safety and efficacy of aesthetic procedures, Dr. Samantha Tay, founder of Nexus Aesthetic Clinic, is emphasizing the importance of prioritizing patient safety through direct, doctor-led care. By personally conducting all patient consultations and administering all injectable treatments, Dr. Tay aims to provide a transparent and reassuring experience for individua
- 김갑성 기자
- 2025-09-12 15:08
Prioritizing Quality and Patient Safety with Digital Transformation, RS Pondok Indah Group Becomes First in Indonesia to Achieve HIMSS EMRAM Stage 7

[ 메디채널 김갑성 기자 ] Setting new standards in healthcare quality and patient safety through digital transformation. JAKARTA, Indonesia, Sept. 12, 2025 -- RS Pondok Indah Group (Pondok Indah Hospital Group) has made history as the first hospital group in Indonesia to achieve the HIMSS Electronic Medical Record Adoption Model (EMRAM) Stage 7, the world's highest quality standard for assessing digital maturity and data management in hospitals. This recognition was awarded to all three hospitals under RS Pondok Indah Group—RS Pondok Indah – Pondok Indah, RS Pondok Indah – Puri Indah, and RS P
- 김갑성 기자
- 2025-09-12 14:14
Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig

NANJING, China, Sept. 12, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB bispecific antibody) as monotherapy or in combination with other agents for the ‌first-line treatment of advanced melanoma‌‌. Opamtistomig‌, a uniquely designed PD-L1/4-1BB bispecific antibody that simultaneously blocks PD-1/L1-mediated immune suppression and enhances 4-1BB-regulated T-cell acti
- 김갑성 기자
- 2025-09-12 12:39
Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more than one year First and only chemotherapy-free combination in the first line setting to show survival improvement of this magnitude in a population with the highest-prevalence of EGFR-mutated lung cancer SINGAPORE, Sept. 12, 2025 -- Johnson & Johnson today announced positive topline results for overall survival (OS) from the Asia cohort of the Phase 3 MARIPOSA study, evaluating amivantamab plus lazertinib as a first-
- 김갑성 기자
- 2025-09-12 11:00
Smartee and Shanghai Ninth People's Hospital Win First Prize at Shanghai Science and Technology Progress Awards

SHANGHAI, Sept. 12, 2025 -- Smartee Denti-Technology, a global innovator in invisible orthodontic solutions, together with Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, has been awarded the First Prize of the Shanghai Science and Technology Progress Award. This prestigious recognition highlights the two institutions' joint achievements in advancing precision surgery for complex craniofacial deformities. Award and Background: The Shanghai Science and Technology Progress Award, established by the Shanghai Municipal People's Gove
- 김갑성 기자
- 2025-09-12 10:03
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration

SUZHOU, China, Sept. 12, 2025 -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been accepted by the National Medical Products Administration (NMPA). KN026 has been applied for as a Class 1 therapeutic biological product and the indication is for use in combination with chemotherapy for the treatment of patients with HER2-positive locally a
- 김갑성 기자
- 2025-09-12 09:51
Amazfit Announces Olympic Medalist Grant Fisher as New Brand Ambassador

[ 메디채널 황정호 기자 ] Elite distance runner joins Amazfit's growing athlete team and will play an active role in product testing and innovation MILPITAS, Calif., Sept. 12, 2025 -- Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced two-time Olympic medalist and American record holder Grant Fisher as the newest addition to its roster of athlete ambassadors. Fisher will collaborate closely with Amazfit on product testing, athlete storytelling, and community engagement as he trains toward the 2028 Olympic Games in Los Angeles. Fisher made
- 황정호 기자
- 2025-09-12 07:30
Psoriatic Disease To Take Center Stage at the UN General Assembly: IFPA Calls for Greater Recognition of Psoriatic Disease During UN High-Level Meetings

STOCKHOLM, Sept. 12, 2025 -- The International Federation of Psoriasis Associations (IFPA) spotlights psoriatic disease at the upcoming UNGA 80 in New York, where world leaders are expected to adopt a new Political Declaration on noncommunicable diseases (NCDs), mental health and well-being. Key Highlights: An estimated 60 million people worldwide are affected by psoriatic disease - a serious, lifelong noncommunicable disease that impacts the skin, joints, and other organs. Psoriasis also increases risks for diabetes, obesity, cardiovascular disease and depres
- 김갑성 기자
- 2025-09-12 00:16
Zhimeng Biopharma's Investigational Drug Approved to Initiate Phase 2 Epilepsy Clinical Trial in China

SHANGHAI, Sept. 12, 2025 -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a Phase 2 clinical trial in China for refractory epilepsy. This follows the CDE's approval in July of this year for Phase 2/3 clinical studies in amyotrophic lateral sclerosis (ALS). The upcoming trial is a randomized, double-blind, placebo-contro
- 김갑성 기자
- 2025-09-12 00:00
Datasea Secures Landmark Agreement for First Acoustic Wearable Technology Contract, Marking Entry into the $1 Trillion Market

Driving the Commercialization of Acoustic Technology in Smart Health Wearables through Solution-Based Service Delivery BEIJING, Sept. 11, 2025 -- Datasea Inc. (NASDAQ: DTSS), a Nevada-based technology company specializing in acoustic high-tech products and AI multimodal digital solutions, today announced that its VIE entity in China, Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd., has signed a service agreement with Hainan Zhixingjian Intelligent Technology Co., Ltd.( "Hainan Zhixingjian"). The two companies will collaborate on the commercialization of aco
- 김갑성 기자
- 2025-09-11 21:30

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 07시 20분